5408-15-1

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-methylpiperazin-1-yl)-1-phenylethanol is used as a psychoactive compound for its potential therapeutic effects in treating conditions such as depression and anxiety. Its psychostimulant properties are being researched for their efficacy in alleviating symptoms associated with these mental health disorders.
Used in Research and Development:
M1PE is utilized in scientific research to explore its psychoactive properties and understand its mechanism of action. This research aims to determine the safety profile and potential efficacy of M1PE in various therapeutic applications, ensuring that its use is beneficial and controlled within appropriate medical contexts.
Used in Regulatory and Control Measures:
Due to its potential for abuse as a psychostimulant and a drug of abuse, 2-(4-methylpiperazin-1-yl)-1-phenylethanol is used in the development of regulatory frameworks and control measures. These measures are designed to ensure that M1PE is used responsibly and within the confines of the law to prevent misuse and protect public health.

Upstream product

• 41298-85-5 2-(4-methylpiperazin-1-yl)-1-phenylethan-1-one 
• 70-11-1 α-bromoacetophenone 
• 109-01-3 1-methyl-piperazine 
• 96-09-3 styrene oxide 

Relevant academic research and scientific papers

Small-Molecule Activator of UNC-51-Like Kinase 1 (ULK1) That Induces Cytoprotective Autophagy for Parkinson's Disease Treatment

UNC-51-like kinase 1 (ULK1), the yeast Atg1 ortholog, is the sole serine-threonine kinase and initiating enzyme in autophagy, which may be regarded as a target in Parkinson's disease (PD). Herein, we discovered a small molecule 33i (BL-918) as a potent activator of ULK1 by structure-based drug design. Subsequently, some key amino acid residues (Arg18, Lys50, Asn86, and Tyr89) were found to be crucial to the binding pocket between ULK1 and 33i by site-directed mutagenesis. Moreover, we found that 33i induced autophagy via the ULK complex in SH-SY5Y cells. Intriguingly, this activator displayed a cytoprotective effect on MPP+-treated SH-SY5Y cells, as well as protected against MPTP-induced motor dysfunction and loss of dopaminergic neurons by targeting ULK1-modulated autophagy in mouse models of PD. Together, these results demonstrate the therapeutic potential to target ULK1, and 33i, the novel activator of ULK1, may serve as a candidate drug for future PD treatment.

Prodrugs of Pyrazolo[3,4-d]pyrimidines: From Library Synthesis to Evaluation as Potential Anticancer Agents in an Orthotopic Glioblastoma Model

Pyrazolo[3,4-d]pyrimidines are potent protein kinase inhibitors with promising antitumor activity but suboptimal aqueous solubility, consequently worth being further optimized. Herein, we present the one-pot two-step procedure for the synthesis of a set o

SEROTONIN REUPTAKE INHIBITORS

A serotonin reuptake inhibitor which can be used in the treatment of depression and which has a decreased occurrence of unwanted side effects. The serotonin reuptake inhibitors are bi-functional organic molecules which combine serotonin transporter reuptake inhibition with serotonin (5-HT,such as 5-HT2A) receptor antagonism in one molecular entity. The serotonin-selective reuptake inhibitor (SSRI) homologue portion of the molecule shows an affinity to the serotonin reuptake transporter (SERT) and has antidepressant properties. The piperazine or piperidine portion of the molecule demonstrates an affinity to 5-HT receptors and restores the undesired side effects of SSRIs.